Butrans Transdermal System delivers continuous release of buprenorphine for seven days, Purdue Pharma said.
Purdue Pharma has jointly developed a Risk Evaluation and Mitigation Strategy (REMS) for Butrans with the US Food and Drug Administration.
Georgetown University adjunct faculty member Joseph Pergolizzi said Butrans may provide healthcare professionals with a new tool for appropriate adult patients with moderate to severe chronic pain who meet the indication of the product.